Nancy Lee Bartlett MD

Hematologic Oncology

Professor, Internal Medicine, Washington University School of Medicine

4921 Parkview Pl# DvSt. Louis, MO 63110
Phone+1 800-647-2098
Fax+1 314-362-3192

Dr. Bartlett is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Bartlett's full profile Already have an account?

Education & Training

Stanford Health Care-Sponsored Stanford UniversityFellowship, Medical Oncology, 1990 - 1993
University of California (San Francisco)Internship, Internal Medicine, 1986 - 1987
WashU MedicineClass of 1986

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

CA State Medical License 1988 - Present
MO State Medical License 1993 - 2027
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification Allscripts Enterprise EHR, Allscripts, 2012

Clinical Trials

Aminocamptothecin in Treating Patients With Refractory or Recurrent Hodgkin's Disease or Non-Hodgkin's Lymphoma
COMPLETED
PHASE2
Etoposide in Treating Patients With Relapsed Non-Hodgkin's Lymphoma
COMPLETED
PHASE2
Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Hodgkin's Lymphoma Start of enrollment: 1999 Jun 17
COMPLETED
PHASE3

Publications & Presentations

PubMed

To B or not to B, that is the question: the role of bleomycin in early stage Hodgkin lymphoma.
David A Russler-Germain, Nancy L Bartlett
Haematologica. 2026-08-01
A Phase I Study of Copanlisib and Venetoclax in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
Jennifer L Crombie, Austin I Kim, Robert Redd, Nancy Bartlett, Victoria Patterson
Clinical Lymphoma, Myeloma & Leukemia. 2026-08-01
From breakthroughs to blueprints: evolving evidence and future directions in relapsed and refractory large B-cell lymphoma.
Manali Kamdar, Nancy L Bartlett
Blood. 2026-06-11

Journal Articles

CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin’s Lymphoma
Mark P Chao, Sonali M Smith, Ranjana Advani, Ian Flinn, Ravindra Majeti, Nancy L Bartlett, Leslie Popplewell, Justin Kline, Nilanjan Ghosh, Ann LaCasce, The New England Journal of Medicine
Rituximab with ABVD vs ABVD for Advanced Stage High-Risk Classical Hodgkin Lymphoma: A Randomized Phase II Study
Francesco Turturro, Luis E Fayad, Anas Younes, Michelle Fanale, Yasuhiro Oki, Hun Ju Lee, Nancy L Bartlett, Haematologica
Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma
Ian W Flinn, Nancy L Bartlett, The New England Journal of Medicine

Abstracts/Posters

The DIAL Study (Dual Immunomodulation in Aggressive Lymphoma): A Randomized Phase 2 Study of CDX-1127 (Varlilumab) in Combination with Nivolumab in Patients with Relap...
Nancy L Bartlett, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Pharmacodynamic Effects and Immune Correlates of Response to the CD20/CD3 Bispecific Antibody Mosunetuzumab in Relapsed or Refractory Non-Hodgkin Lymphoma
Nancy L Bartlett, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Romidepsin in Combination with Gemcitabine, Oxaliplatin, and Dexamethasone Shows Durable Responses in Aggressive Lymphomas
Nancy L. Bartlett, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019

Lectures

Managing cytokine release syndrome (CRS) and neurotoxicity with step-fractionated dosing of mosunetuzumab in relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma (NHL).
ASCO Annual Meeting 2019 - Chicago, IL - 6/3/2019
Brentuximab Vedotin with Chemotherapy for Stage 3/4 Classical Hodgkin Lymphoma (cHL): 4-Year Update of the Echelon-1 Study
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Brentuximab Vedotin with Chemotherapy in Adolescents and Young Adults (AYA) with Stage III or IV Hodgkin Lymphoma: A Subgroup Analysis from the Phase 3 Echelon-1 Study
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

At ASH, Regeneron Plays Catch-up with Its Next Cancer DrugsDecember 12th, 2022
$Bispecific Antibody Mosunetuzumab in Relapsed or Refractory Follicular Lymphoma$
Bispecific Antibody Mosunetuzumab in Relapsed or Refractory Follicular LymphomaJuly 12th, 2022
Pulling Back the Curtain: Bill Blum, MD, and Kristie Blum, MDMarch 1st, 2021

Grant Support

WASHINGTON UNIVERSITY / SITEMAN CANCER CENTER LEAD ACADEMIC SITEWASHINGTON UNIVERSITY2019–2032
Wumc Cancer And Leukemia Group BNational Cancer Institute2009–2012
Data And Safety MonitoringNational Cancer Institute2010–2011
Wumc-Cancer And Leukemia Group BNational Cancer Institute2003–2008
Quality Assurance And Safety MonitoringNational Cancer Institute2004